MediciNova

MEDICINOVA INC

MediciNova Inc is a biopharmaceutical company. The company acquires and develops small-molecule therapeutics for the treatment of diseases with unmet medical needs with a specific focus on the U.S. market. Its products portfolio includes therapeutics such as MN-001, MN-166, MN-221 etc. The firm's current strategy is to focus its development activities on therapeutics for neurological disorders and fibrotic diseases.

Amazon, Crowdstrike, Autodesk, Dell, And Tesla: Why These 5 Stocks Are On Investors' Radars Today

News

Initiation

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

ADSK

MNOV

PRCT

VKTX

This Autodesk Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

movers image

Intraday Update

Movers

AAOI

AGMH

AIXI

AMAT

APDN

ASST

ATPC

AUUD

AVTX

BNRG

Chemomab Therapeutics Ltd. - American Depositary Shares

CMMB

CNFR

FEDU

GERN

INTC

IOBT

KROS

LITB

MRVL

MSGM

NVAX

NVCR

NVMI

PCVX

PSNY

QNTM

RXRX

SGRP

SHLS

SIFY

SLXN

STRL

TCBP

WINT

Why Recursion Pharmaceuticals Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday&#39;s Mid-Day Session

Penny Stocks

Small Cap

ABTS

AKLI

DRCT

DXYZ

FRGE

HKIT

HOOD

JOAN

LUXH

MESO

MIRA

MRDB

NCNO

NUVB

PAYS

PRGS

STKS

Shares of  MariaDB plc  (NYSE: MRDB) rose sharply in today’s pre-market trading after Progress Software (NASDAQ: PRGS) announced that it is possibly considering an offer for the company.

Why MariaDB Shares Are Trading Higher By Around 100%; Here Are 20 Stocks Moving Premarket

MediciNova Inc

Management

Press Releases

General

MediciNova Chief Business Officer David H. Crean, Ph.D. Assumes Communications Role Overseeing Investor Engagement and Public Relations

Health Care

Legal

MediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-166 (ibudilast) for the Post-COVID Condition

MediciNova Announces Acceptance of Abstract Regarding MN-166 (ibudilast) in COMBAT-ALS Clinical Trial for Presentation at the 2024 Annual NEALS (Northeast Amyotrophic Lateral Sclerosis Consortium) Meeting

MediciNova Announces Abstract Regarding MN-166 (ibudilast) in COMBAT-ALS Clinical Trial Accepted for Poster Presentation at the 35th International Symposium on ALS / MND

MediciNova to Support NIH-Funded Expanded Access Clinical Trial to Evaluate MN166 (ibudilast) in Amyotrophic Lateral Sclerosis (ALS)

MediciNova Announces Update of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS patients (COMBAT-ALS) at the 2024 Annual NEALS Meeting (Northeast Amyotrophic Lateral Sclerosis Consortium)

MediciNova Given Notice of Monetary Damages Due Under Patent Settlement of Sanofi-Novartis

MediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-001 for Triglyceride Synthesis in the Liver

MediciNova CEO Yuichi Iwaki Provides Corporate Update in Letter to Stockholders

MediciNova Presents Study Update and Interim Analysis of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS (COMBAT-ALS Clinical Trial) at the 35th International Symposium on ALS/MND

Acumen Pharmaceuticals, Inc. - Common Stock

Acumen Pharmaceuticals

Adicet Bio

Artiva Biotherapeutics, Inc. - Common Stock

Artiva Biotherapeutics

Assembly Biosciences, Inc. - Common Stock

Assembly Biosciences

Aerovate Therapeutics, Inc. - Common Stock

Aerovate Therapeutics

Avalo Therapeutics

BeyondSpring

Cabaletta Bio

CAMP4 Therapeutics Corporation - Common Stock

Camp4 Therapeutics

Cibus

Corbus Pharmaceuticals Holdings, Inc. - Common Stock

Corbus Pharmaceuticals

Genenta Science S.p.A. - American Depositary Shares

Genenta Science

HilleVax

IGM Biosciences

I-MAB

Inovio Pharmaceuticals, Inc. - Common Stock

Inovio Pharmaceuticals

Inozyme Pharma

IO Biotech

Invivyd

Jasper Therapeutics, Inc. - Class A Common Stock

Jasper Therapeutics

Macrogenics

Pyxis Oncology

Quince Therapeutics

TScan Therapeutics

Vistagen Therapeutics, Inc. - Common Stock

Vistagen Therapeutics

D. Boral Capital

Comments

MediciNova

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga